Ewan M Tomeny retweeted
Today's Lancet climate and health report presents 56 indicators of health and climate change across FIVE domains. (Download the report for free from the Lancet website). Here is a thread of some of the key findings. #Lancetclimate24 (1)
Ewan M Tomeny retweeted
Fantastic PharmacoEconomics article by @Ewmoto, Eve Worrall & @lstmnews team, rethinking #TB morbidity quantification. Disability weights essential for TB DALY calculations but, with gaps in current approaches, this review asks "what are we weighting for?"
link.springer.com/article/10…
Ewan M Tomeny retweeted
Health Economic results from the Stage 2 STREAM #ClinicalTrial have been published today in @LancetGH. @BertieSquire, @eworrall1, @JasonMadan, @laura_rosu1, @ewmoto. Find out more: rb.gy/uhwyq7
Happy to share our study in @GlobalHealthBMJ contributing valuable evidence to post-TB morbidity agenda from a longitudinal post-treatment cohort.@beckyn_respPT @1Gn1991 @JasonMadan @eworrall1 @ChakayaJm @JamieRylance @BertieSquire @LSTMnews #postTB #DALY gh.bmj.com/content/7/5/e0076…
Ewan M Tomeny retweeted
Tao Chen & colleagues estimate the cost-effectiveness of intensive blood pressure intervention in Chinese populations at high risk for #CardiovascularDisease plos.io/2OJUk0n
Ewan M Tomeny retweeted
Wrapping up #WorldTBDay2021 with the recording of #LSTM's virtual seminar:
Prof @BertieSquire, @laura_rosu1, Ewan Tomeny & an international panel of experts on 'About time: Advancing the clinical & public health management of drug resistant #tuberculosis bit.ly/3ckJxTD
An important piece from my colleague Dr Obasi.
(1/3) Reposted as 3 linked tweets: I am writing in @TheLancet about academia but the message - #NoExcellenceWithoutEquity- applies to all sectors where measures of “Excellence” are blind to fairness or inclusion. thelancet.com/journals/lance…
Ewan M Tomeny retweeted
#STREAM1 paper, the first ever within-trial economic evaluation of shortened regimen for #DRTB has been published today in @WHOBulletin
Shortened multidrug resistant #tuberculosis (MDR-TB) regimen reduces costs for health systems by 21 to 25% per patient and helps patients return to work, study shows.
bit.ly/3f7WQ94 #endTB #DRTB, #costeffectiveness, #patientcosts











